Efficacy and Safety Study of Budesonide to Treat Oral Chronic Graft vs Host Disease (cGvHD)

Inclusion Criteria: * Karnofsky \>= 70 * Oral chronic GvHD after allogeneic haematopoietic stem cell transplantation * Oral cGvHD of erosive and/or ulcerative type * NIH scale \>= 3 * Resistant oral cGvHD with no oral response to conventional primary treatment Exclusion Criteria: * Uncertain diagnosis of resistant oral cGvHD * Symptomatic oral cGvHD of hyperkeratotic type solely * Current active oral bacterial, viral, or fungal infection * Unwilling to forego concurrent treatment for mucosal lesions and/or related oral pain * Requiring addition of new systemic therapy including steroids, or radiation therapy * Local intestinal infection * Abnormal hepatic function or liver cirrhosis * If careful medical monitoring is not ensured: tuberculosis, cardiovascular disease, diabetes mellitus, osteoporosis, active peptic ulcer disease, glaucoma, cataract, infection * Second line treatment of oral cGvHD with topical steroids